Pre-Made Olamkicept Biosimilar, Fusion Protein targeting IL6 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 for drug discovery and mechanism of action (MOA) research

Pre-Made Olamkicept Biosimilar, Fusion Protein targeting IL6 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Olamkicept, also known as soluble gp13Fc or sgp13Fc (other designations are FE 99931, FE31, TJ31) is an immunosuppressive drug candidate, which selectively blocks activities of the cytokine Interleukin-6, which are mediated by the soluble Interleukin-6.[1] Interleukin-6 is a cytokine, which plays a dominant role in the regulation of the immune response and also in autoimmunity. Furthermore, Interleukin-6 has been demonstrated to be involved in the regulation of metabolism and body weight.[2] Interleukin-6 also has many activities on neural cells.[3] The biochemical principle was invented by the German biochemist Stefan Rose-John and it was further developed into a biotech compound by the Conaris Research Institute AG, which gave an exclusive world-wide license to the Swiss-based biopharmaceutical company Ferring Pharmaceuticals.[4] In December 216, Ferring and the biotech company I-MAB signed a licensing agreement granting I-MAB exclusive rights in Asia to Olamkicept for the treatment of autoimmune disease.[5]

The olamkicept is an extracellular portion of gp130 fused to the constant portion of a human IgG1 antibody. Olamkicept is an immunosuppressive drug candidate, which selectively blocks activities of the cytokine Interleukin-6, which are mediated by the soluble Interleukin-6.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-932-1mg	1mg	3090
GMP-Bios-INN-932-10mg	10mg	Inquiry
GMP-Bios-INN-932-100mg	100mg	Inquiry
GMP-Bios-INN-932-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Olamkicept Biosimilar, Fusion Protein targeting IL6 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BSF-2/BSF2/CDF/HGF/HSF/IFN-beta-2/IFNB2/IL-6
INN Name	Olamkicept
Target	IL6
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [IL6ST (interleukin 6 signal transducer, "interleukin 6 signal transducer (gp130, oncostatin M receptor)", CD130, GP130, "gp130, oncostatin M receptor", "Interleukin-6 receptor subunit beta") 23-617]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [IL6ST (interleukin 6 signal transducer, "interleukin 6 signal transducer (gp130, oncostatin M receptor)", CD130, GP130, "gp130, oncostatin M receptor", "Interleukin-6 receptor subunit beta") 23-617]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Ferring Pharmaceuticals (Saint-Prex Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0